Loading…

Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice

To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice. MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October...

Full description

Saved in:
Bibliographic Details
Published in:Urology (Ridgewood, N.J.) N.J.), 2020-11, Vol.145, p.204-210
Main Authors: Lebastchi, Amir H., Russell, Christopher M., Niknafs, Yashar S., Eyrich, Nicholas W., Chopra, Zoey, Botbyl, Rachel, Kabeer, Rana, Osawa, Takahiro, Siddiqui, Javed, Siddiqui, Rabia, Davenport, Matthew S., Mehra, Rohit, Tomlins, Scott A., Kunju, Lakshimi P., Chinnaiyan, Arul M., Wei, John T., Tosoian, Jeffrey J., Morgan, Todd M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93
cites cdi_FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93
container_end_page 210
container_issue
container_start_page 204
container_title Urology (Ridgewood, N.J.)
container_volume 145
creator Lebastchi, Amir H.
Russell, Christopher M.
Niknafs, Yashar S.
Eyrich, Nicholas W.
Chopra, Zoey
Botbyl, Rachel
Kabeer, Rana
Osawa, Takahiro
Siddiqui, Javed
Siddiqui, Rabia
Davenport, Matthew S.
Mehra, Rohit
Tomlins, Scott A.
Kunju, Lakshimi P.
Chinnaiyan, Arul M.
Wei, John T.
Tosoian, Jeffrey J.
Morgan, Todd M.
description To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice. MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients undergoing biopsy was compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model. Of 248 patients, 134 (54%) proceeded to prostate biopsy. MPS was significantly higher in biopsied patients (median 29 vs14, P < .001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth quintiles, respectively (P < .001). MPS association with biopsy persisted upon stratification by mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous (odds ratio [OR] 1.05, 95%; confidence interval [CI] 1.04-1.08;
doi_str_mv 10.1016/j.urology.2020.07.042
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2432863494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090429520309560</els_id><sourcerecordid>2432863494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EokvhEUA-lkPC2PHaMRdUFgqVWlHR9mw5zqR4lcTBTpD2GXhpvOyWK6eRRt8_M__8hLxmUDJg8t22XGLow8Ou5MChBFWC4E_Iiq25KrTW66dkBaChEFyvT8iLlLYAIKVUz8lJxZVSlYIV-X05TNbNNHR0_oH0encTQ5rtjLcuRKRn1ze3b-kdpkyMf4lN70fvbE8_ofPJ77uB3o8txodAH8X0ow9T2r2n3zEt_ZzoRQwDtXQTxhmHKUQbd_Tc2RYH77IqX-AdviTPOtsnfHWsp-T-4vPd5mtx9e3L5eb8qnCC8blgTFUtCgWSV9Bo1TSWNdgxkLWsG-644AyalkOrHGuqrmOiRS3r2taZs7o6JWeHuVMMP5fszQw-Oex7O2JYkuGi4rWshBYZXR9Ql52liJ2Zoh_y9YaB2edgtuaYg9nnYECZnEPWvTmuWJoB23-qx8dn4MMBwGz0l8dokvM4Omx9RDebNvj_rPgD9kudKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2432863494</pqid></control><display><type>article</type><title>Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice</title><source>Elsevier</source><creator>Lebastchi, Amir H. ; Russell, Christopher M. ; Niknafs, Yashar S. ; Eyrich, Nicholas W. ; Chopra, Zoey ; Botbyl, Rachel ; Kabeer, Rana ; Osawa, Takahiro ; Siddiqui, Javed ; Siddiqui, Rabia ; Davenport, Matthew S. ; Mehra, Rohit ; Tomlins, Scott A. ; Kunju, Lakshimi P. ; Chinnaiyan, Arul M. ; Wei, John T. ; Tosoian, Jeffrey J. ; Morgan, Todd M.</creator><creatorcontrib>Lebastchi, Amir H. ; Russell, Christopher M. ; Niknafs, Yashar S. ; Eyrich, Nicholas W. ; Chopra, Zoey ; Botbyl, Rachel ; Kabeer, Rana ; Osawa, Takahiro ; Siddiqui, Javed ; Siddiqui, Rabia ; Davenport, Matthew S. ; Mehra, Rohit ; Tomlins, Scott A. ; Kunju, Lakshimi P. ; Chinnaiyan, Arul M. ; Wei, John T. ; Tosoian, Jeffrey J. ; Morgan, Todd M.</creatorcontrib><description>To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice. MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients undergoing biopsy was compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model. Of 248 patients, 134 (54%) proceeded to prostate biopsy. MPS was significantly higher in biopsied patients (median 29 vs14, P &lt; .001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth quintiles, respectively (P &lt; .001). MPS association with biopsy persisted upon stratification by mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous (odds ratio [OR] 1.05, 95%; confidence interval [CI] 1.04-1.08; &lt;.001) and binary (OR 7.76, 95%; CI 4.14-14.5; P &lt; .001) variable. Many patients (46%) undergoing clinical MPS testing as an alternative to immediate prostate biopsy were able to avoid biopsy. Increasing MPS was strongly associated with biopsy rates. These findings were robust to use of mpMRI.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/j.urology.2020.07.042</identifier><identifier>PMID: 32777370</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antigens, Neoplasm - urine ; Biopsy ; Clinical Decision-Making ; Cohort Studies ; Humans ; Male ; Middle Aged ; Multiparametric Magnetic Resonance Imaging ; Prostate - diagnostic imaging ; Prostate - pathology ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - urine</subject><ispartof>Urology (Ridgewood, N.J.), 2020-11, Vol.145, p.204-210</ispartof><rights>2020</rights><rights>Copyright © 2020. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93</citedby><cites>FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32777370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lebastchi, Amir H.</creatorcontrib><creatorcontrib>Russell, Christopher M.</creatorcontrib><creatorcontrib>Niknafs, Yashar S.</creatorcontrib><creatorcontrib>Eyrich, Nicholas W.</creatorcontrib><creatorcontrib>Chopra, Zoey</creatorcontrib><creatorcontrib>Botbyl, Rachel</creatorcontrib><creatorcontrib>Kabeer, Rana</creatorcontrib><creatorcontrib>Osawa, Takahiro</creatorcontrib><creatorcontrib>Siddiqui, Javed</creatorcontrib><creatorcontrib>Siddiqui, Rabia</creatorcontrib><creatorcontrib>Davenport, Matthew S.</creatorcontrib><creatorcontrib>Mehra, Rohit</creatorcontrib><creatorcontrib>Tomlins, Scott A.</creatorcontrib><creatorcontrib>Kunju, Lakshimi P.</creatorcontrib><creatorcontrib>Chinnaiyan, Arul M.</creatorcontrib><creatorcontrib>Wei, John T.</creatorcontrib><creatorcontrib>Tosoian, Jeffrey J.</creatorcontrib><creatorcontrib>Morgan, Todd M.</creatorcontrib><title>Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice. MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients undergoing biopsy was compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model. Of 248 patients, 134 (54%) proceeded to prostate biopsy. MPS was significantly higher in biopsied patients (median 29 vs14, P &lt; .001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth quintiles, respectively (P &lt; .001). MPS association with biopsy persisted upon stratification by mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous (odds ratio [OR] 1.05, 95%; confidence interval [CI] 1.04-1.08; &lt;.001) and binary (OR 7.76, 95%; CI 4.14-14.5; P &lt; .001) variable. Many patients (46%) undergoing clinical MPS testing as an alternative to immediate prostate biopsy were able to avoid biopsy. Increasing MPS was strongly associated with biopsy rates. These findings were robust to use of mpMRI.</description><subject>Aged</subject><subject>Antigens, Neoplasm - urine</subject><subject>Biopsy</subject><subject>Clinical Decision-Making</subject><subject>Cohort Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiparametric Magnetic Resonance Imaging</subject><subject>Prostate - diagnostic imaging</subject><subject>Prostate - pathology</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - urine</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkcFu1DAQhi0EokvhEUA-lkPC2PHaMRdUFgqVWlHR9mw5zqR4lcTBTpD2GXhpvOyWK6eRRt8_M__8hLxmUDJg8t22XGLow8Ou5MChBFWC4E_Iiq25KrTW66dkBaChEFyvT8iLlLYAIKVUz8lJxZVSlYIV-X05TNbNNHR0_oH0encTQ5rtjLcuRKRn1ze3b-kdpkyMf4lN70fvbE8_ofPJ77uB3o8txodAH8X0ow9T2r2n3zEt_ZzoRQwDtXQTxhmHKUQbd_Tc2RYH77IqX-AdviTPOtsnfHWsp-T-4vPd5mtx9e3L5eb8qnCC8blgTFUtCgWSV9Bo1TSWNdgxkLWsG-644AyalkOrHGuqrmOiRS3r2taZs7o6JWeHuVMMP5fszQw-Oex7O2JYkuGi4rWshBYZXR9Ql52liJ2Zoh_y9YaB2edgtuaYg9nnYECZnEPWvTmuWJoB23-qx8dn4MMBwGz0l8dokvM4Omx9RDebNvj_rPgD9kudKw</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Lebastchi, Amir H.</creator><creator>Russell, Christopher M.</creator><creator>Niknafs, Yashar S.</creator><creator>Eyrich, Nicholas W.</creator><creator>Chopra, Zoey</creator><creator>Botbyl, Rachel</creator><creator>Kabeer, Rana</creator><creator>Osawa, Takahiro</creator><creator>Siddiqui, Javed</creator><creator>Siddiqui, Rabia</creator><creator>Davenport, Matthew S.</creator><creator>Mehra, Rohit</creator><creator>Tomlins, Scott A.</creator><creator>Kunju, Lakshimi P.</creator><creator>Chinnaiyan, Arul M.</creator><creator>Wei, John T.</creator><creator>Tosoian, Jeffrey J.</creator><creator>Morgan, Todd M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202011</creationdate><title>Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice</title><author>Lebastchi, Amir H. ; Russell, Christopher M. ; Niknafs, Yashar S. ; Eyrich, Nicholas W. ; Chopra, Zoey ; Botbyl, Rachel ; Kabeer, Rana ; Osawa, Takahiro ; Siddiqui, Javed ; Siddiqui, Rabia ; Davenport, Matthew S. ; Mehra, Rohit ; Tomlins, Scott A. ; Kunju, Lakshimi P. ; Chinnaiyan, Arul M. ; Wei, John T. ; Tosoian, Jeffrey J. ; Morgan, Todd M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Antigens, Neoplasm - urine</topic><topic>Biopsy</topic><topic>Clinical Decision-Making</topic><topic>Cohort Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiparametric Magnetic Resonance Imaging</topic><topic>Prostate - diagnostic imaging</topic><topic>Prostate - pathology</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lebastchi, Amir H.</creatorcontrib><creatorcontrib>Russell, Christopher M.</creatorcontrib><creatorcontrib>Niknafs, Yashar S.</creatorcontrib><creatorcontrib>Eyrich, Nicholas W.</creatorcontrib><creatorcontrib>Chopra, Zoey</creatorcontrib><creatorcontrib>Botbyl, Rachel</creatorcontrib><creatorcontrib>Kabeer, Rana</creatorcontrib><creatorcontrib>Osawa, Takahiro</creatorcontrib><creatorcontrib>Siddiqui, Javed</creatorcontrib><creatorcontrib>Siddiqui, Rabia</creatorcontrib><creatorcontrib>Davenport, Matthew S.</creatorcontrib><creatorcontrib>Mehra, Rohit</creatorcontrib><creatorcontrib>Tomlins, Scott A.</creatorcontrib><creatorcontrib>Kunju, Lakshimi P.</creatorcontrib><creatorcontrib>Chinnaiyan, Arul M.</creatorcontrib><creatorcontrib>Wei, John T.</creatorcontrib><creatorcontrib>Tosoian, Jeffrey J.</creatorcontrib><creatorcontrib>Morgan, Todd M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lebastchi, Amir H.</au><au>Russell, Christopher M.</au><au>Niknafs, Yashar S.</au><au>Eyrich, Nicholas W.</au><au>Chopra, Zoey</au><au>Botbyl, Rachel</au><au>Kabeer, Rana</au><au>Osawa, Takahiro</au><au>Siddiqui, Javed</au><au>Siddiqui, Rabia</au><au>Davenport, Matthew S.</au><au>Mehra, Rohit</au><au>Tomlins, Scott A.</au><au>Kunju, Lakshimi P.</au><au>Chinnaiyan, Arul M.</au><au>Wei, John T.</au><au>Tosoian, Jeffrey J.</au><au>Morgan, Todd M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>2020-11</date><risdate>2020</risdate><volume>145</volume><spage>204</spage><epage>210</epage><pages>204-210</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><abstract>To evaluate the association of the MyProstateScore (MPS) urine test on the decision to undergo biopsy in men referred for prostate biopsy in urology practice. MPS testing was offered as an alternative to immediate biopsy in men referred to the University of Michigan for prostate biopsy from October 2013 through October 2016. The primary endpoint was the decision to perform biopsy. The proportion of patients undergoing biopsy was compared to predicted risk scores from the Prostate Cancer Prevention Trial risk calculator (PCPTrc). Analyses were stratified by the use of multiparametric magnetic resonance imaging (mpMRI). The associations of PCPTrc, MPS, and mpMRI with the decision to undergo biopsy were explored in a multivariable logistic regression model. Of 248 patients, 134 (54%) proceeded to prostate biopsy. MPS was significantly higher in biopsied patients (median 29 vs14, P &lt; .001). The use of biopsy was strongly associated with MPS, with biopsy rates of 26%, 38%, 58%, 90%, and 85% in the first through fifth quintiles, respectively (P &lt; .001). MPS association with biopsy persisted upon stratification by mpMRI. On multivariable analysis, MPS was strongly associated with the decision to undergo biopsy when modeled as both a continuous (odds ratio [OR] 1.05, 95%; confidence interval [CI] 1.04-1.08; &lt;.001) and binary (OR 7.76, 95%; CI 4.14-14.5; P &lt; .001) variable. Many patients (46%) undergoing clinical MPS testing as an alternative to immediate prostate biopsy were able to avoid biopsy. Increasing MPS was strongly associated with biopsy rates. These findings were robust to use of mpMRI.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32777370</pmid><doi>10.1016/j.urology.2020.07.042</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0090-4295
ispartof Urology (Ridgewood, N.J.), 2020-11, Vol.145, p.204-210
issn 0090-4295
1527-9995
language eng
recordid cdi_proquest_miscellaneous_2432863494
source Elsevier
subjects Aged
Antigens, Neoplasm - urine
Biopsy
Clinical Decision-Making
Cohort Studies
Humans
Male
Middle Aged
Multiparametric Magnetic Resonance Imaging
Prostate - diagnostic imaging
Prostate - pathology
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - pathology
Prostatic Neoplasms - urine
title Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A04%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20the%20MyProstateScore%20(MPS)%20Test%20on%20the%20Clinical%20Decision%20to%20Undergo%20Prostate%20Biopsy:%20Results%20From%20a%20Contemporary%20Academic%20Practice&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Lebastchi,%20Amir%20H.&rft.date=2020-11&rft.volume=145&rft.spage=204&rft.epage=210&rft.pages=204-210&rft.issn=0090-4295&rft.eissn=1527-9995&rft_id=info:doi/10.1016/j.urology.2020.07.042&rft_dat=%3Cproquest_cross%3E2432863494%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c412t-1173de4706230b97bba1bef106868b2c24210bd20d7c1b3ff14de9688a81bea93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2432863494&rft_id=info:pmid/32777370&rfr_iscdi=true